UK MHRA · November 12, 2025

Guidance: Early Access to Medicines Scheme: Overview

EAMS provides early access to medicines for life-threatening or seriously debilitating conditions showing major therapeutic advantage.

High obligation Sector Pharmaceuticals Market Access & Reimbursement UK Pharmaceuticals

The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeutics.

Read the official source ↗

Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.